After an anonymous tip raised concerns about pesticide testing protocols at Rapid Analytics, the Mississippi State Department of Health (MSDH) has implemented an administrative hold on all medical cannabis products tested at the Natchez-based lab. Lab spokesperson Mamie Henry stated, “They have no basis for anything, except an anonymous call, which has shut the entire industry down pretty much because we do 70% of the testing for the state.”
This administrative halt prevents dispensaries from selling any cannabis products that Rapid Analytics has tested until further instructions are provided by MSDH. A communication from the Mississippi Medical Cannabis Program confirmed that while some products are on hold, not all dispensaries have been required to close.
Emergency Response to Anonymous Complaint
On Wednesday morning, MSDH contacted Rapid Analytics regarding the anonymous allegation, leading to an urgent Zoom meeting to discuss the lab’s procedures and cannabis testing reports from the previous months. Mississippi has two licensed testing labs: Rapid Analytics and Steep Hill Mississippi in Jackson. All cannabis tested by Steep Hill is still deemed safe for patient consumption.
Cannabis growers must submit their products for testing at one of these labs before they can distribute them to dispensaries. Some growers, like 74 Suns in Canton, opt to test with both facilities. Consultant Hardy Case indicated that 74 Suns’ products remain available for sale since they received approval from Steep Hill.
Despite having products that have passed testing, some dispensaries are unable to sell them due to the hold. “It’s just sitting there, even though that product may be perfectly fine,” Case noted.
Impacts on Patients and Dispensaries
Henry assured stakeholders that Rapid Analytics is responding swiftly and professionally to resolve the situation and is retesting all cannabis samples, even though MSDH does not mandate additional analyses. “We are the most respected and most used lab in the entire state, and so I don’t know who would make this ‘anonymous’ call,” she stated.
The challenges of entering the Mississippi medical cannabis market make this situation particularly concerning for patients and small business owners. Case highlighted the hurdles the industry has faced in the state and expressed disappointment that the issue with Rapid Analytics wasn’t resolved quickly to avoid patient shortages.
Both dispensaries and cultivators are awaiting guidance from MSDH on how to proceed with the retesting or potential disposal of affected medical cannabis products. Henry affirmed that Rapid Analytics has already supplied the necessary documentation to MSDH to validate their testing protocols.
The timing of the testing concerns is also problematic, as it coincides with the holiday season. With many dispensaries potentially facing product delays or recalls, this could lead to localized shortages in medical cannabis supply. Case remarked on the impact this hold has on patients in rural areas, who may have to travel further for limited cannabis options. Some dispensaries could face severe financial repercussions due to lost sales during this period.
A statement from the Mississippi Medical Cannabis Program emphasized their commitment to safeguarding patient health and ensuring that all products meet regulatory standards through expedited retesting.
